Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing

Area of Science:

• Hematology
• Immunology
• Genetics

Background:

• Sickle cell disease (SCD) is an inherited disorder characterized by hemoglobin S, leading to anemia, infections, and vaso-occlusive crises (VOC).
• Pathophysiology of SCD complications like VOC and delayed hemolytic transfusion reactions (DHTR) is complex, involving cellular interactions and increasingly, complement activation.
• Current treatments for SCD complications are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To provide clinicians with an understanding of the complement system in the context of SCD.
• To review the role and mechanisms of complement activation in both asymptomatic and symptomatic SCD patients.
• To explore the therapeutic potential of complement inhibition for managing SCD and its complications.

Main Methods:

• Literature review focusing on the complement system's role in sickle cell disease.
• Analysis of studies investigating complement activation in various SCD clinical states.
• Examination of preclinical and clinical data on complement inhibitors in SCD.

Main Results:

• Complement activation is increasingly recognized as a significant factor in SCD pathophysiology.
• Evidence suggests complement plays a role in both the chronic hemolysis and acute vaso-occlusive events in SCD.
• Complement inhibition, exemplified by eculizumab in DHTR, shows promise for treating SCD-related complications.

Conclusions:

• The complement system is a critical, yet often overlooked, player in sickle cell disease pathogenesis.
• Targeting complement activation presents a promising new therapeutic strategy for addressing the unmet needs in SCD management.
• Further research into complement pathways and targeted inhibition is warranted to develop effective treatments for SCD.